MY193724A - Immune modulation - Google Patents
Immune modulationInfo
- Publication number
- MY193724A MY193724A MYPI2015703226A MYPI2015703226A MY193724A MY 193724 A MY193724 A MY 193724A MY PI2015703226 A MYPI2015703226 A MY PI2015703226A MY PI2015703226 A MYPI2015703226 A MY PI2015703226A MY 193724 A MY193724 A MY 193724A
- Authority
- MY
- Malaysia
- Prior art keywords
- ara
- fusion protein
- immune modulation
- peanut
- derivative
- Prior art date
Links
- 235000017060 Arachis glabrata Nutrition 0.000 abstract 2
- 241001553178 Arachis glabrata Species 0.000 abstract 2
- 235000010777 Arachis hypogaea Nutrition 0.000 abstract 2
- 235000018262 Arachis monticola Nutrition 0.000 abstract 2
- 239000013566 allergen Substances 0.000 abstract 2
- 108020001507 fusion proteins Proteins 0.000 abstract 2
- 102000037865 fusion proteins Human genes 0.000 abstract 2
- 235000020232 peanut Nutrition 0.000 abstract 2
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 abstract 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 abstract 1
- 230000015556 catabolic process Effects 0.000 abstract 1
- 238000006731 degradation reaction Methods 0.000 abstract 1
- 230000010039 intracellular degradation Effects 0.000 abstract 1
- 150000007523 nucleic acids Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/863—Poxviral vectors, e.g. entomopoxvirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24041—Use of virus, viral particle or viral elements as a vector
- C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24142—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24171—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Botany (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361852239P | 2013-03-15 | 2013-03-15 | |
| PCT/AU2014/000286 WO2014138824A1 (en) | 2013-03-15 | 2014-03-17 | Immune modulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY193724A true MY193724A (en) | 2022-10-27 |
Family
ID=51535630
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2015703226A MY193724A (en) | 2013-03-15 | 2014-03-17 | Immune modulation |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11173206B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3685853A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP6549042B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR102125594B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN109517842A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2014231734B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2906735C (cg-RX-API-DMAC7.html) |
| DK (1) | DK2968528T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2909750T3 (cg-RX-API-DMAC7.html) |
| HK (1) | HK1219436A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL241596B (cg-RX-API-DMAC7.html) |
| MY (1) | MY193724A (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ630642A (cg-RX-API-DMAC7.html) |
| RU (2) | RU2662927C2 (cg-RX-API-DMAC7.html) |
| SG (1) | SG11201507657QA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014138824A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2914286T3 (da) | 2012-10-30 | 2021-11-08 | Aravax Pty Ltd | Hidtil ukendte immunterapeutiske molekyler og anvendelser deraf |
| WO2014138824A1 (en) * | 2013-03-15 | 2014-09-18 | Sementis Limited | Immune modulation |
| JP7007534B2 (ja) | 2013-09-25 | 2022-01-24 | アラヴァックス ピーティーワイ リミテッド | 新規免疫療法組成物およびその使用 |
| MX2019001919A (es) | 2016-08-19 | 2019-09-04 | Sementis Ltd | Vacunas virales. |
| KR20230152035A (ko) * | 2021-02-01 | 2023-11-02 | 에쓰티 피에이치아이 테라퓨틱스 컴퍼니 리미티드 | 표적 단백질 분해 시스템 및 이의 응용 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6037135A (en) | 1992-08-07 | 2000-03-14 | Epimmune Inc. | Methods for making HLA binding peptides and their uses |
| US5773705A (en) * | 1992-12-31 | 1998-06-30 | Wisconsin Alumni Research Foundation | Ubiquitin fusion protein system for protein production in plants |
| WO2001039799A2 (en) | 1999-12-06 | 2001-06-07 | Panacea Pharmaceuticals, Llc. | Passive desensitization |
| US8623379B2 (en) | 2000-03-02 | 2014-01-07 | Emory University | Compositions and methods for generating an immune response |
| US7265208B2 (en) * | 2001-05-01 | 2007-09-04 | The Regents Of The University Of California | Fusion molecules and treatment of IgE-mediated allergic diseases |
| EP1407033B1 (en) * | 2002-05-16 | 2006-01-11 | Bavarian Nordic A/S | Intergenic regions as insertion sites in the genome of modified vaccinia virus ankara (mva) |
| JP2009513532A (ja) * | 2003-07-10 | 2009-04-02 | サイトス バイオテクノロジー アーゲー | パッケージ化ウイルス様粒子 |
| CN101001872A (zh) * | 2004-04-16 | 2007-07-18 | 宏观基因有限公司 | FcγRIIB－特异性抗体及其使用方法 |
| CN100374152C (zh) * | 2005-12-23 | 2008-03-12 | 中国农业大学 | 一种过敏性反应抑制剂 |
| EP1835031A1 (en) | 2006-03-14 | 2007-09-19 | Paul-Ehrlich-Institut Bundesamt für Sera und Impfstoffe | Use of a recombinant modified vaccinia virus Ankara (MVA) for the treatment of type I hypersensitivity in a living animal including humans |
| DK2153841T4 (en) * | 2008-08-15 | 2016-02-15 | Circassia Ltd | Vaccine comprising Amb a 1 peptides for use in the treatment of ambrosieallergi |
| GB201104537D0 (en) * | 2011-03-17 | 2011-05-04 | Cambridge Entpr Ltd | Treatment for peanut allergy |
| WO2014138824A1 (en) * | 2013-03-15 | 2014-09-18 | Sementis Limited | Immune modulation |
-
2014
- 2014-03-17 WO PCT/AU2014/000286 patent/WO2014138824A1/en not_active Ceased
- 2014-03-17 RU RU2015144308A patent/RU2662927C2/ru active
- 2014-03-17 EP EP20156953.0A patent/EP3685853A1/en not_active Withdrawn
- 2014-03-17 DK DK14763738.3T patent/DK2968528T3/da active
- 2014-03-17 US US14/777,457 patent/US11173206B2/en active Active
- 2014-03-17 CA CA2906735A patent/CA2906735C/en active Active
- 2014-03-17 SG SG11201507657QA patent/SG11201507657QA/en unknown
- 2014-03-17 JP JP2015561833A patent/JP6549042B2/ja active Active
- 2014-03-17 MY MYPI2015703226A patent/MY193724A/en unknown
- 2014-03-17 HK HK16107611.6A patent/HK1219436A1/zh unknown
- 2014-03-17 RU RU2018121086A patent/RU2709771C2/ru active
- 2014-03-17 AU AU2014231734A patent/AU2014231734B2/en active Active
- 2014-03-17 KR KR1020157029396A patent/KR102125594B1/ko active Active
- 2014-03-17 NZ NZ630642A patent/NZ630642A/en unknown
- 2014-03-17 ES ES14763738T patent/ES2909750T3/es active Active
- 2014-03-17 CN CN201811364128.0A patent/CN109517842A/zh active Pending
- 2014-03-17 KR KR1020197033558A patent/KR102212253B1/ko active Active
- 2014-03-17 CN CN201480024524.2A patent/CN105163756A/zh active Pending
- 2014-03-17 EP EP14763738.3A patent/EP2968528B1/en active Active
-
2015
- 2015-09-16 IL IL241596A patent/IL241596B/en active IP Right Grant
-
2019
- 2019-03-26 JP JP2019059511A patent/JP2019134707A/ja active Pending
-
2021
- 2021-10-14 US US17/501,305 patent/US20220088189A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2906735A1 (en) | 2014-09-18 |
| KR20160002771A (ko) | 2016-01-08 |
| US11173206B2 (en) | 2021-11-16 |
| JP6549042B2 (ja) | 2019-07-24 |
| CN109517842A (zh) | 2019-03-26 |
| JP2016513963A (ja) | 2016-05-19 |
| KR20190130665A (ko) | 2019-11-22 |
| RU2662927C2 (ru) | 2018-07-31 |
| ES2909750T3 (es) | 2022-05-10 |
| HK1219436A1 (zh) | 2017-04-07 |
| SG11201507657QA (en) | 2015-10-29 |
| CA2906735C (en) | 2020-03-24 |
| AU2014231734A1 (en) | 2015-10-08 |
| RU2018121086A3 (cg-RX-API-DMAC7.html) | 2019-03-05 |
| DK2968528T3 (da) | 2022-03-28 |
| KR102125594B1 (ko) | 2020-06-24 |
| CN105163756A (zh) | 2015-12-16 |
| IL241596B (en) | 2018-05-31 |
| EP3685853A1 (en) | 2020-07-29 |
| AU2014231734B2 (en) | 2018-03-15 |
| RU2018121086A (ru) | 2019-03-05 |
| EP2968528A4 (en) | 2016-10-12 |
| NZ630642A (en) | 2016-01-29 |
| JP2019134707A (ja) | 2019-08-15 |
| WO2014138824A1 (en) | 2014-09-18 |
| EP2968528A1 (en) | 2016-01-20 |
| KR102212253B1 (ko) | 2021-02-04 |
| US20220088189A1 (en) | 2022-03-24 |
| RU2709771C2 (ru) | 2019-12-19 |
| RU2015144308A (ru) | 2017-04-20 |
| EP2968528B1 (en) | 2022-02-23 |
| US20160030552A1 (en) | 2016-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124740T1 (el) | Συνθεσεις που περιλαμβανουν συνθετiκα πολυνουκλεοτιδια που κωδικοποιουν crispr σχετικες πρωτεϊνες και συνθετικα sgrnas και μεθοδοι χρησης | |
| CR20140565A (es) | Proteínas de fusión de interleuquina 10 y usos de las mismas | |
| PH12018501355A1 (en) | Rsv f protein mutants | |
| WO2015015448A3 (en) | Engineered polypeptide conjugates using transglutaminase | |
| EA201690529A1 (ru) | Способы модификации клетки-хозяина | |
| MX391311B (es) | Acidos nucleicos modificados dirigidos a acidos nucleicos. | |
| FR3021319B1 (fr) | Peptides, compositions les comprenant et utilisations notamment cosmetiques | |
| EP3741849A3 (en) | Protease variants and polynucleotides encoding same | |
| MX2019003214A (es) | Formulaciones de proteina de inmunoglobulina del dominio variable dual estable. | |
| WO2015052543A3 (en) | Malaria vaccination | |
| WO2014116846A3 (en) | Methods and compositions for modulating an immune response | |
| MX2017008817A (es) | Composiciones y metodos para la glicosilacion de proteinas. | |
| MX2014009285A (es) | Alergenos del fleo de los prados y metodos y usos para la modulacion de respuesta inmune. | |
| CR20170197A (es) | Proteinas de variantes de secuencias de aminoacidos de cry1da1 activas para lepidópteros | |
| WO2017025179A8 (en) | A transglutamine tag for efficient site-specific bioconjugation | |
| MX382218B (es) | Variantes de lipasa y polinucleotidos que las codifican. | |
| MX2015014424A (es) | Construcciones de proteinas mitocondriales y sus usos. | |
| MY193724A (en) | Immune modulation | |
| HK1258649A1 (zh) | 来自病原体的免疫原性抗原鉴定以及与临床效力的相关性 | |
| MY188100A (en) | Compositions and methods vectors for inducing an enhanced immune response using poxvirus vectors | |
| MY176200A (en) | Binding polypeptides having a mutated scaffold | |
| WO2014150748A3 (en) | Stabilized single human cd4 domains and fusion proteins | |
| PH12015501854A1 (en) | Factor ix polypeptide formulations | |
| WO2014151834A3 (en) | Methods and compositions relating to anti-ccr7 antigen binding proteins | |
| MA37749A1 (fr) | Vaccins contre les virus réassortis de la fièvre catarrhale et de la peste équine |